Browse the evidence

In older adults (61+ years), a low variety of energy-dense foods predicts lower energy intake and lower BMI, while a high variety of micronutrient-dense foods counterbalances age-related micronutrient deficiencies.

If you are over 60 and struggling to maintain weight or energy, do not restrict your diet to only 'healthy' low-calorie foods. Increasing the variety of energy-dense foods (like those with some fat/carbs) can help increase energy intake and BMI. Conversely, to ensure you get enough vitamins, you must eat a wide variety of nutrient-dense foods (fruits, veggies, dairy, grains), as older bodies are less efficient at absorbing nutrients.

Long-term use of GLP-1 receptor agonists (GLP-1RAs) reduces the incidence of knee surgery and slows cartilage loss velocity in knee osteoarthritis (KOA) patients with comorbid type 2 diabetes, primarily mediated by significant weight loss rather than direct anti-inflammatory effects.

If you have knee osteoarthritis and type 2 diabetes, using GLP-1RAs (like semaglutide or liraglutide) for at least two years can significantly reduce your risk of needing knee surgery and slow down cartilage wear. This benefit comes mainly from the weight loss these drugs cause, which reduces stress on your knees. While they also help with pain, the structural protection is largely weight-dependent. To maximize benefits, combine GLP-1RA therapy with resistance training to preserve muscle mass.

Maintenance of weight loss is physiologically distinct from active weight loss, characterized by a 'perfect physiological storm' of increased appetite and decreased energy expenditure that actively opposes weight maintenance.

Accept that maintaining weight loss is biologically harder than losing it. Your body will fight back with increased hunger and lower energy expenditure. To succeed, you must implement strategies that account for this 'storm,' such as higher physical activity levels to offset the metabolic slowdown, rather than relying solely on willpower or extreme restriction.

Leptin repletion to pre-weight-loss levels reverses most physiological adaptations (hypometabolism and hyperphagia) in weight-reduced individuals, proving that low leptin drives these adaptations.

While leptin therapy is not currently a standard commercial treatment for obesity, this research highlights that the biological drive to regain weight is mediated by low leptin levels. This underscores why weight maintenance is so difficult and why future pharmacotherapies targeting these pathways (like GLP-1 agonists which mimic satiety signals) are crucial.

An isocaloric ketogenic diet (5% carbohydrate, 80% fat) increases fasting inflammatory markers (CRP, adiponectin) and cholesterol (total, LDL, HDL) compared to a baseline diet (50% carbohydrate, 35% fat) in men with overweight or class I obesity.

If you switch to a strict ketogenic diet (80% fat, 5% carbs) while keeping your calories the same, expect your cholesterol (including LDL and HDL) and inflammatory marker (CRP) levels to rise compared to a standard diet. This effect was observed in men with overweight or obesity over 4 weeks. Monitor your lipids and inflammation if you adopt this diet.

An isocaloric ketogenic diet decreases insulin-mediated antilipolysis (the ability of insulin to suppress fat breakdown) compared to a baseline diet, regardless of the meal consumed.

On a ketogenic diet, your body's fat cells become less responsive to insulin's signal to stop breaking down fat. This means insulin is less effective at suppressing fat release, even if your blood sugar control remains stable. This is a key metabolic shift to understand when managing body composition on keto.

An isocaloric ketogenic diet significantly lowers fasting triglycerides but raises fasting total, HDL, and LDL cholesterol compared to a baseline diet in men with overweight or obesity.

Switching to a ketogenic diet will likely lower your triglycerides but raise your total, LDL, and HDL cholesterol. This mixed effect means you should monitor your full lipid panel, not just triglycerides, to assess cardiovascular risk.

Dietary composition, particularly high carbohydrate intake, can reduce post-weight-loss metabolic expenditure by approximately 200 kcal/day compared to higher fat intakes, contributing to weight regain.

After weight loss, be mindful of high-carbohydrate diets, especially if you have insulin resistance. Higher fat or lower carbohydrate intakes may help preserve metabolic rate, making it easier to maintain your weight.

AOM therapy requires monitoring and potential dose reduction of concomitant medications for diabetes and hypertension due to rapid weight loss and improved metabolic parameters.

If you take medication for diabetes or high blood pressure, tell your doctor you are starting an AOM. Your doses may need to be lowered quickly as you lose weight to prevent dangerous drops in blood sugar or blood pressure.

Higher resistance training volume (3 sets vs 1 set) yields greater muscle hypertrophy and strength gains, but this benefit is contingent upon the individual's capacity for ribosome biogenesis (total RNA accumulation).

If you are new to resistance training, doing 3 sets per exercise will likely yield better muscle and strength gains than doing just 1 set. However, your body's ability to produce ribosomes (total RNA) determines how much benefit you get from those extra sets. If you are short on time, 1 set is still effective, but 3 sets is superior for maximizing growth.

Abbreviated behavioral weight loss interventions (8 in-person sessions) supported by mobile technology or standard coaching produce clinically meaningful weight loss at 6 months, comparable to full-intensity programs, but this superiority over self-guided treatment dissipates by 12 months once intervention components cease.

An abbreviated weight loss program (8 sessions + coaching) using mobile technology or standard methods can help you lose a clinically meaningful amount of weight (approx. 5-6% of body weight) over 6 months. However, this benefit is not sustained after 12 months if you stop using the tools and coaching. To maintain weight loss, you likely need ongoing support or a transition to sustainable habits, as the 'boost' from the intervention fades when it ends.

In low-income regions (Sub-Saharan Africa), rising income significantly increases the intake of processed meat and sugar-sweetened beverages, whereas in high-income regions, these categories often become inferior goods (intake declines with rising income).

If you are in a developing economy, rising income does not automatically mean you will eat healthier. In fact, as income rises in these regions, people tend to buy more processed meats and sugary drinks. To maintain health, you must consciously prioritize whole foods and limit processed items, as market forces will naturally push you toward them.

Fruit intake is the food category most responsive to rising income globally, particularly among older women, suggesting it is a 'superior good' that increases with wealth.

For older women, increasing income is a powerful lever to improve diet quality by increasing fruit consumption. If you are in a low-income region, focus on adding fruit to your diet as your financial situation improves, as this is the category most likely to increase with your budget.

Dropping a BMI category (e.g., from obese to overweight or overweight to normal) during adulthood, even if the weight loss is not sustained, is associated with reduced carotid intima media thickness (cIMT) and improved cardiovascular risk factors compared to maintaining a higher BMI category.

You do not need to keep the weight off forever to get heart benefits. If you lose enough weight to move down a category (e.g., from obese to overweight), your arteries and blood pressure improve, even if you gain some weight back later. This suggests that any attempt to reduce weight in adulthood is valuable for long-term cardiovascular health.

Metformin is the primary first-line oral treatment for type 2 diabetes across all age groups due to its efficacy, versatility, and cost-effectiveness, with benefits extending to cardiovascular and potential anti-neoplastic properties.

Start with metformin as your primary medication. It is the standard, effective, and affordable choice for managing blood sugar. While it may cause mild stomach issues initially, it is generally well-tolerated and helps protect your heart and kidneys over the long term.

In patients with type 2 diabetes or prediabetes and established cardiovascular risk, maintaining a BMI of 25–35 kg/m² (overweight to mild obesity) is associated with lower all-cause and cardiovascular mortality compared to a normal BMI of 22–24.9 kg/m².

If you have diabetes or prediabetes along with other heart disease risks, do not aggressively pursue weight loss to reach a 'normal' BMI (22-25). Your data suggests you are safest in the overweight to mild obesity range (BMI 25-35). Focus on cardiovascular health markers rather than the scale number.

Resistance exercise performed at low intensity (30% 1RM) to volitional fatigue stimulates myofibrillar protein synthesis rates equally to high intensity (90% 1RM) exercise, challenging the necessity of heavy loads for muscle growth.

You do not need to lift heavy weights to build muscle. If you lift a lighter weight (30% of your max) until you physically cannot complete another repetition, your muscles will grow just as effectively as they would with heavy weights. Focus on reaching failure, not just moving heavy loads.

Nonexercise activity thermogenesis (NEAT) accounts for the vast majority of nonresting metabolic rate and its modulation predicts susceptibility to fat gain during overfeeding.

Focus on increasing your daily non-exercise movement. Standing, walking, and even fidgeting contribute significantly to your total calorie burn. You don't need to hit the gym to impact your energy balance; simply moving more throughout the day (NEAT) is a powerful lever for managing body weight.

Metabolic surgery reduces the 10-year risk of major adverse cardiovascular events (all-cause mortality, coronary artery events, heart failure, and nephropathy) in patients with type 2 diabetes and obesity compared to usual care, as quantified by the Individualized Diabetes Complications (IDC) Risk Scores.

If you have type 2 diabetes and obesity, ask your doctor about using a risk calculator (like the IDC Risk Scores) to compare your 10-year risk of heart failure, kidney disease, and death with current medications versus metabolic surgery. The data suggests surgery may significantly lower these risks for many patients, helping you make an informed decision based on your specific health profile.

Lifestyle interventions for type 2 diabetes often fail to maintain weight loss and glycemic improvements long-term after the intervention ends.

Expect some weight regain after a structured program ends. To mitigate this, seek ongoing support, such as maintenance groups or periodic check-ins, as lifestyle interventions alone often fail to sustain long-term results without continued engagement.

Higher circulating levels of plasma very-long-chain saturated fatty acids (VLCSFAs: C20:0, C22:0, C24:0) are associated with a significantly lower risk of incident coronary heart disease (CHD) in US men and women.

This observational study suggests that higher levels of specific very-long-chain saturated fatty acids (C20:0, C22:0, C24:0) in the blood are linked to a lower risk of heart disease. However, this does not mean you should intentionally consume more of these fats, as their source and overall dietary context are critical. The findings highlight the complexity of lipid metabolism and suggest that blood markers of these fatty acids may serve as useful indicators of cardiovascular health rather than direct targets for supplementation.

Circulating very-long-chain saturated fatty acids (VLCSFAs) in plasma are associated with favorable cardiovascular risk markers, including higher HDL-C, lower triglycerides, and higher adiponectin.

Higher levels of specific saturated fatty acids in the blood are linked to better cholesterol profiles (higher HDL, lower triglycerides) and lower inflammation. This suggests these fatty acids may play a role in metabolic health, distinct from other types of saturated fats.

Newer FDA-approved pharmacological interventions (Lorcaserin, Phentermine-Topiramate ER) produce greater weight loss than older medications but remain less effective than bariatric surgery and carry risks of central nervous system and cardiovascular adverse effects.

Newer weight loss drugs like Lorcaserin and Qsymia work better than older options but still produce less weight loss than surgery. They carry risks of side effects like nausea or mood changes, so they require medical supervision. They are an option if surgery is not desired or possible.

Lorcaserin, a selective serotonin 2C receptor agonist, produces modest but clinically significant weight loss (mean 3.2-5.0 kg) compared to placebo, though tolerance may develop over two years of treatment.

Lorcaserin offers a modest weight loss benefit (approx. 3-5 kg) over lifestyle changes alone for obese patients. It works by targeting serotonin receptors to reduce appetite. However, tolerance can develop, leading to weight regain in the second year. It is only prescribed if you lose at least 5% of your body weight in the first 12 weeks; otherwise, it is stopped.